Renaissance Technologies LLC Has $13.08 Million Position in Castle Biosciences, Inc. $CSTL

Renaissance Technologies LLC grew its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 8.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 532,800 shares of the company’s stock after acquiring an additional 39,700 shares during the quarter. Renaissance Technologies LLC’s holdings in Castle Biosciences were worth $13,080,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of CSTL. Federated Hermes Inc. bought a new position in Castle Biosciences during the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. bought a new stake in Castle Biosciences in the fourth quarter valued at approximately $35,000. Jones Financial Companies Lllp increased its stake in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after purchasing an additional 976 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on CSTL shares. Weiss Ratings cut shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. KeyCorp set a $35.00 price objective on Castle Biosciences in a research note on Friday, May 29th. BTIG Research reduced their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.43.

Key Stories Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Revenue significantly exceeded expectations: Second-quarter revenue was approximately $103.5 million, up 20.1% year over year and above analyst estimates near $86 million-$88 million. Gross profit increased 16.5% to $79.8 million. Castle Biosciences Reports Second Quarter 2026 Results
• Positive Sentiment: Loss was narrower than expected: Adjusted loss was $0.07 per share, compared with the consensus estimate of a $0.41-$0.44 loss. The operating loss narrowed to $3.1 million, supporting the view that improving scale may help profitability over time. Castle Biosciences Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Full-year outlook was raised: Castle now expects 2026 revenue of $365 million to $375 million, above the approximately $353.2 million analyst consensus. The higher outlook strengthens the growth narrative and likely provided the main catalyst for the stock’s advance. Castle Biosciences Lifts 2026 Outlook After Q2 Growth
• Neutral Sentiment: Liquidity remains solid: The company generated $15.2 million in operating cash flow and ended the quarter with $62.1 million in cash, while maintaining relatively low leverage. However, capital spending was $8.7 million and net profitability has not yet been achieved. Castle Biosciences Q2 2026 Earnings Call Transcript
• Negative Sentiment: Insider selling remains a risk signal: Chief Executive Officer Derek Maetzold and other executives have reported stock sales, with the transactions conducted under pre-arranged Rule 10b5-1 plans. While these sales do not necessarily indicate deteriorating business conditions, the absence of reported insider purchases may temper investor enthusiasm.

Insiders Place Their Bets

In related news, insider Derek J. Maetzold sold 3,622 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $24.16, for a total value of $87,507.52. Following the sale, the insider directly owned 11,812 shares of the company’s stock, valued at approximately $285,377.92. The trade was a 23.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.42, for a total transaction of $209,670.12. Following the completion of the sale, the chief operating officer directly owned 21,874 shares in the company, valued at $534,163.08. This represents a 28.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 55,025 shares of company stock worth $1,252,199. 6.10% of the stock is currently owned by company insiders.

Castle Biosciences Price Performance

NASDAQ CSTL opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. The stock has a market cap of $849.24 million, a price-to-earnings ratio of -42.42 and a beta of 1.00. The business has a 50 day simple moving average of $22.76 and a 200 day simple moving average of $26.52. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.16%. Analysts anticipate that Castle Biosciences, Inc. will post -1.56 earnings per share for the current fiscal year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.